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Abstract 
Background: Cardiotoxic effects of local anesthetics (LAs) involve inhibition of 
NaV1.5 voltage-gated Na
+ channels. Metastatic breast and colon cancer cells also 
express NaV1.5, predominantly the neonatal splice variant (nNaV1.5) and their 
inhibition by LAs reduces invasion and migration. It may be advantageous to target 
cancer cells while sparing cardiac function through selective blockade of nNaV1.5 
and/or by preferentially affecting inactivated NaV1.5, which predominate in cancer 
cells. We tested the hypotheses that lidocaine and levobupivacaine differentially 
affect 1) adult (aNaV1.5) and nNaV1.5 and 2) the resting and inactivated states of 
NaV1.5.  
Methods: The whole-cell voltage-clamp technique was used to evaluate the actions 
of lidocaine and levobupivacaine on recombinant NaV1.5 channels expressed in 
HEK-293 cells. Cells were transiently transfected with cDNAs encoding either 
aNaV1.5 or nNaV1.5. Voltage protocols were applied to determine depolarising 
potentials that either activated or inactivated 50% of maximum conductance (V½ 
activation and V½ inactivation, respectively). 
Results: Lidocaine and levobupivacaine potently inhibited aNaV1.5 (IC50 mean (SD): 
20 (22) and 1 (0.6) µM, respectively) and nNaV1.5 (IC50 mean (SD): 17 (10) and 3 
(1.6) µM, respectively) at a holding potential of -80 mV. IC50s differed significantly 
between lidocaine and levobupivacaine with no influence of splice variant. 
Levobupivacaine induced a statistically significant depolarising shift in the V½ 
activation for aNaV1.5 (mean (SD) from -32 (4.6) mV to -26 (8.1) mV), but had no 
effect on the voltage-dependence of activation of nNaV1.5. Lidocaine had no effect 
on V½ activation of either variant, but caused a significantly greater depression of 
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maximum current mediated by nNaV1.5 compared to aNaV1.5. Similar statistically 
significant shifts in the V½ inactivation (approximately -10 mV) occurred for both LAs 
and NaV1.5 variants. Levobupivacaine (1 µM) caused a significantly greater slowing 
of recovery from inactivation of both variants than did lidocaine (10 µM). Both LAs 
caused approximately 50% tonic inhibition of aNaV1.5 or nNaV1.5 when holding at -
80 mV. Neither LA caused tonic block at a holding potential of either -90 or -120 mV, 
voltages at which there was little steady-state inactivation. Higher concentrations of 
either lidocaine (300 µM) or levobupivacaine (100 µM) caused significantly more 
tonic block at -120 mV.  
Conclusions: These data demonstrate that low concentrations of the LAs exhibit 
inactivation-dependent block of NaV1.5, which may provide a rationale for their use 
to safely inhibit migration and invasion by metastatic cancer cells without 
cardiotoxicity. 
Key Points Summary:  
Question: Can lidocaine and/or levobupivacaine be used to preferentially target the 
cardiac NaV1.5 variant expressed by metastatic colon and breast cancer cells? 
Findings: Low concentrations of both local anesthetics preferentially inhibit 
inactivated NaV1.5 with minor differences in their effects on the adult and neonatal 
splice variants. 
Meaning: NaV1.5 channels on cancer cells may be preferentially targeted by low 
concentrations of lidocaine and levobupivacaine by virtue of prevalent inactivation in 
these cells. 
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Introduction 
Voltage-activated Na+ channels (VASCs) are targets for local anaesthetics (LAs). 
There are 10 subtypes of human VASCs; those expressed by sensory neurons 
mediate the beneficial analgesic effects of LAs 1. However, LAs are non-selective, 
inhibiting all VASCs including the cardiac isoform, NaV1.5, an action that contributes 
to their cardiotoxicity 2,3. Furthermore, at high concentrations they interact with 
additional ion channels in the heart and central nervous system.  
In addition to their classical actions LAs have additional effects. Several 
retrospective studies suggest that LAs are beneficial during tumour excision, 
reducing recurrence and metastases in patients who received regional anesthesia 4-
7. These effects might be indirect, through the reduced requirement for general 
anesthesia and opioids, factors that may adversely affect the stress response, the 
immune system and natural killer cells 8. LAs might also directly affect cancer cells.  
NaV1.5 channels are not only expressed in the heart, they are also expressed by 
breast and colon cancer cells in which their activity contributes to migration and 
invasion 9-12. In keeping with this, inhibition of NaV1.5 by LAs attenuates colon cancer 
invasion 9,10 and xenograft studies demonstrate that VASC inhibitors reduce cancer 
progression in vivo 13,14.  
Intravenous administration of LAs, during surgical tumour excision, might be 
advantageous to optimise their putative direct beneficial effects on circulating cancer 
cells 8. Lidocaine and levobupivacaine are commonly used to provide analgesia 
during surgical tumour excision. However, blood concentrations during their 
intravenous administration reach the low micromolar range well below 
concentrations usually examined in studies of interactions of LAs with VASCs 15,16.  
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Metastatic breast and colon cancer cells predominantly express the neonatal splice 
variant of NaV1.5 (nNaV1.5), which contains amino acids encoded by exon 6a in 
place of those encoded by exon 6b in the aNaV1.5 adult variant 
10,12. Therefore, it 
may be advantageous to target cancer cells while sparing adult cardiac function 
through selectively blocking nNaV1.5. Alternatively, preferential block of the 
inactivated state of NaV1.5, which predominates in colon cancer cells due to their 
depolarized resting potential 10, may provide an approach for their selective blockade 
by LAs.  
We used the whole-cell voltage-clamp technique to evaluate the actions of 
micromolar concentrations of lidocaine and levobupivacaine on recombinant nNaV1.5 
and aNaV1.5 channels expressed in HEK-293 cells. We tested the hypotheses that 
the LAs differentially affect 1) aNaV1.5 and nNaV1.5 and 2) the resting and 
inactivated states of these NaV1.5 variants.   
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Materials and methods 
Cell culture and transfection 
Human embryonic kidney (HEK-293) cells were grown and maintained in Dulbecco’s 
Modified Eagle Medium (DMEM), supplemented with 10% foetal bovine serum and 
1% penicillin-streptomycin (Invitrogen, Paisley, UK). Confluent cells were sub-
cultured every 3-4 days and plated onto 35 mm dishes at low density for 
electrophysiological experiments. All cells were maintained in an incubator at 37oC 
and 5 % CO2. 
HEK-293 cells were transfected using the calcium phosphate precipitation method 
with human SCN5A (adult or neonatal) in pcDNA3.1 vector at 1 µg/dish, along with 
cDNA for green fluorescent protein (GFP) at 0.1 µg/dish 10. GFP was used to identify 
transfected cells.  
Electrophysiology 
Currents were recorded from HEK-293 cells transiently expressing aNav1.5 or 
nNav1.5 using the whole-cell voltage-clamp technique. Currents were recorded using 
an Axopatch 200B patch-clamp amplifier, low-pass filtered at 2 KHz, digitised by 
Digidata 1320A interface, sampled at 4 KHz and acquired using pClamp8 software 
(Molecular Devices, CA, USA). Pipettes were formed from borosilicate glass 
capillaries and had resistances between 1.5 and 3 MΩ when filled with intracellular 
solution, containing (in mM) the following: 130 CsCl, 15 NaCl, 2 MgCl2, 10 EGTA 
and 10 HEPES. The extracellular solution contained (in mM) the following: 140 NaCl, 
4.7 KCl, 1.2 MgCl2, 2.5 CaCl2, 10 glucose and 10 HEPES. Series resistance 
compensation was ≥ 85 %, in order to minimise voltage errors, which were only 
accepted if below 4 mV, taking into consideration the peak current and the access 
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resistance. A holding potential of –80 mV was used in all protocols unless stated 
otherwise. All solutions were bath applied and recordings were made under 
continuous perfusion of bath solutions at room temperature. No corrections were 
made for liquid junction potential compensation.  
Data analysis 
Current amplitudes were measured using pClamp10 (Molecular devices, CA, USA). 
Plots of the voltage-dependence of activation were derived from current-voltage 
relationships. The driving force at each holding potential (up to +20 mV) was 
determined from the theoretical Na+ equilibrium potential, in order to calculate Na+ 
conductance. Conductances were normalised to the respective peak values in each 
cell. For the voltage-dependence of inactivation, the amplitude of the available 
current was normalised to peak amplitude values for each cell. Activation and 
inactivation data were fitted with Boltzmann functions, as described previously 10. 
Concentration-response data were fitted with a logistic function 10. Average 
parameters were determined from fits to data acquired from individual cells. For 
recovery from inactivation, currents were normalised to peak values and data were 
fitted using the sum of two exponential functions. Time constants were determined 
from data obtained from individual cells. Weighted time constants (τw) were 
calculated as follows: 
𝜏𝑤 = (𝜏𝑓 × 𝐴𝑓) + (𝜏𝑠 × 𝐴𝑠) 
where τf and τs are the fast and slow time constants, respectively, and Af and As are 
the relative amplitudes of the fast and slow components, respectively. Non-linear 
regression fitting and graphing were performed using GraphPad Prism software (La 
Jolla, CA, USA). 
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Statistical analysis 
All data are presented as mean (SD). Comparisons of current density values, V½ 
activation, V½ inactivation and their slope values before and after LA application 
were performed using the paired t-test (two-tailed). Pairwise comparisons between 
low and high concentrations of LA at hyperpolarised potentials were performed using 
the 2 sample t-test (two-tailed). Comparisons involving the extent of inhibition by LAs 
at different holding potentials (-80, -90 and -120 mV) were performed using a one-
way ANOVA. Subsequent multiple pairwise comparisons between each holding 
potential were corrected using the Tukey method. All comparisons interrogating the 
influence of both LA and splice variants were performed using a two-way ANOVA. In 
all cases, an interaction between the two factors (LA and splice variant) was also 
tested. Statistically significant influences of either factor or a significant interaction 
between the factors were further analysed with pairwise comparisons corrected with 
the Bonferroni method. These pairwise comparisons were performed interrogating 
the difference between each LA to control within each splice variant, and also across 
the two splice variants. Comparisons of IC50 values were performed on log 
transformed data to preserve normality. P-values < 0.05 were considered statistically 
significant for t-tests. For multiple comparisons, corrected by the Bonferroni method, 
the alpha value was 0.05. Adjusted p-values are reported throughout the study. 
Statistical analyses were performed using IBM SPSS 22 (Armonk, NY, USA). 
The number of biological replicates for this study were chosen on the basis of our 
previous work with similar in vitro experiments 10 enabling detection of differences 
≥10% in our parameters of interest. We considered differences <10% unlikely to be 
physiologically meaningful. 
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Results  
Concentration-dependence of lidocaine and levobupivacaine inhibition of 
NaV1.5 variants 
We established the potency of lidocaine and levobupivacaine as inhibitors of 
aNaV1.5 and nNaV1.5 (Figure 1A & B). Peak current amplitudes recorded in the 
presence of LAs were normalised to control and plotted as a concentration-response 
relationship (Figure 1C & D). Supplementary table 1 contains the fit parameters. We 
used a two-way ANOVA to analyse differences in mean IC50 and Hill coefficient 
values between the LAs and splice variants. There was no significant influence of 
splice variant on IC50 (F1,20 = 1.8; p = 0.2). However, the LAs did have different 
potencies (F1,20 = 41; p < 0.0001). A simple pairwise comparison with a Bonferroni 
correction revealed levobupivacaine to be more potent than lidocaine at either 
aNaV1.5 or nNaV1.5 (p < 0.0001 and p = 0.001, respectively; Supp. table 1). In 
general, levobupivacaine was ~10-fold more potent than lidocaine. There were no 
differences in the Hill coefficients between either LA or splice variants (F1,20 = 0.08; p 
= 0.78; F1,20 = 1.5; p = 0.24, respectively, two-way ANOVA). In subsequent 
experiments, we used 10 µM lidocaine and 1 µM levobupivacaine (approximately 
equally effective concentrations; Fig. 1).  
Lidocaine and levobupivacaine affect the voltage-dependence of NaV1.5 
activation  
Current-voltage relationships were established in the absence or presence of 
lidocaine (10 µM) or levobupivacaine (1 µM). A representative example of the 
currents mediated by nNaV1.5 is shown in Figure 2A. Peak current amplitudes were 
expressed as current densities, averaged and plotted against voltage (Fig. 2B & C). 
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Statistically significant (paired t-test) reductions in nNaV1.5 current density caused by 
the presence of LAs are indicated with an asterisk (Fig. 2B & C). Data for aNaV1.5 
are similar and therefore not shown.  
Plots of the voltage-dependence of activation were fitted with Boltzmann functions 
(Fig. 2D - G). The fit parameters are summarised in Supplementary table 2. 
Lidocaine (10 µM) did not affect the V½ activation for either variant (versus control; 
paired t-test; Supp. table 2). By contrast, levobupivacaine (1 µM) significantly shifted 
the V½ activation of aNaV1.5, but not nNaV1.5 (versus control; paired t-test; Supp. 
table 2). In light of this differential effect of levobupivacaine, we compared the 
change in the V½ activation (Δ V½) using a two-way ANOVA (Fig. 2H). We found a 
significant effect of the variant on Δ V½ (F1,33 = 10; p = 0.003), but no significant 
influence of the LA used (F1,33 = 0.10; p = 0.32), and also no significant interaction 
between the splice variant and LA used (F1,33 = 2.7; p = 0.11). A pairwise 
comparison using a Bonferroni correction revealed that levobupivacaine caused a 
significantly larger shift in V½ of activation in aNaV1.5, than nNaV1.5 (Fig. 2H). 
The LAs altered the shape of the activation curves, both significantly increasing the 
slope parameters for both aNaV1.5 and nNaV1.5 (versus control; Supp. table 2). We 
analysed the extent of change (∆ slope) with a two-way ANOVA (Fig. 2I). We found 
no significant influence of either LA (F1,33 = 1.5; p = 0.23) or splice variant (F1,33 = 
1.8; p = 0.19), suggesting that the degree of change in the slope parameter is similar 
(Fig. 2I). 
Lidocaine and levobupivacaine show a preference for the inactivated state of 
both NaV1.5 splice variants  
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We examined the influence of lidocaine (10 µM) and levobupivacaine (1 µM) on 
inactivation of currents. We applied 100 ms prepulses from -140 mV to -10 mV, 
followed by an activating step to 0 mV to examine the proportion of channels 
available for activation. The plots of voltage-dependence of inactivation and the 
associated Boltzmann fits are shown in Figure 3A to 3D, with fitting parameters 
summarised in Supplementary table 2. Both LAs caused a statistically significant 
hyperpolarizing shift in the V½ of inactivation for both variants (paired t-test; Supp. 
table 2). The magnitude of ∆ V½ was neither dependent on the LA (F1,33 = 0.05; p = 
0.83) nor the splice variant (F1,33 = 0.35; p = 0.56; two-way ANOVA; Fig. 3E). Both 
LAs significantly increased the slope for nNaV1.5 (paired t-test; Supp. table 2). For 
aNaV1.5, only lidocaine significantly increased the slope (Supp. table 2).  
The maximum available current at -140 mV appears less depressed for aNaV1.5 in 
the presence of lidocaine (Fig. 3A). Indeed, a comparison of the maximum inhibition 
(from the Boltzmann fits) revealed a significant (paired t-test) reduction for 
levobupivacaine on both variants and lidocaine on only nNaV1.5 (Supp. table 2). We 
analysed the maximum inhibition using a two-way ANOVA (Fig. 3F). We found no 
significant influence of either LA (F1,33 = 0.11; p = 0.75) or splice variant (F1,33 = 0.26; 
p = 0.62), but a significant interaction between the two (F1,33 = 8.7; p = 0.006). A 
simple effects paired comparison with a Bonferroni correction revealed that 
levobupivacaine caused a greater reduction in the maximal available current than 
lidocaine in aNaV1.5 (p = 0.03), but not nNaV1.5. Also, lidocaine caused a greater 
inhibition of the maximal available current mediated by nNaV1.5 than that mediated 
by aNaV1.5 (p = 0.009; Fig. 3F). 
Inhibition by lidocaine and levobupivacaine is dependent on the inactivated 
state 
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Low concentrations of lidocaine or levobupivacaine shifted the V½ of inactivation to 
more hyperpolarised potentials, consistent with a potent action of these LAs to 
stabilise the inactivated state (Fig. 3). These experiments were performed with a 
holding potential of -80 mV at which there was approximately 40% steady-state 
inactivation. To test the hypothesis that inhibition by LAs requires inactivation we 
investigated tonic inhibition at -80, -90 and -120 mV. Currents were first recorded in 
control conditions. Stimulation was subsequently stopped and cells were exposed to 
lidocaine (10 µM) or levobupivacaine (1 µM) for 120 s. The extent of reduction of the 
first current following LA exposure revealed the magnitude of tonic inhibition. 
Representative examples of tonic inhibition by lidocaine for nNaV1.5 are shown in 
Figure 4A. Robust inhibition was observed at -80 mV. However, negligible inhibition 
occurred at -90 mV and -120 mV (Fig. 4B & C). There were significant differences 
(one-way ANOVA) in the inhibition at the three holding potentials for aNaV1.5 (F2,12 = 
17; p < 0.0001 for lidocaine, F2,9 = 26; p < 0.0001 for levobupivacaine; Fig. 4B) and 
nNaV1.5 (F2,8 = 23; p = 0.001 for lidocaine, F2,9 = 15; p = 0.001 for levobupivacaine; 
Fig. 4C). Using a post-hoc Tukey’s comparison, we found a significant reduction in 
tonic inhibition for aNaV1.5 between -80 mV and -90 mV (p = 0.001 for lidocaine; p = 
0.001 for levobupivacaine), and between -80 mV and -120 mV (p = 0.001 for 
lidocaine; p < 0.0001 for levobupivacaine). A similar relationship was observed for 
nNaV1.5 (-80 mV vs -90 mV, p = 0.001 for lidocaine; p = 0.001 for levobupivacaine; -
80 mV vs -120 mV, p = 0.01 for lidocaine; p = 0.001 for levobupivacaine; Fig. 4C).  
Inhibition of resting NaV1.5 by lidocaine and levobupivacaine occurs at high 
concentrations  
Neither lidocaine (10 µM) nor levobupivacaine (1 µM) had a significant impact on 
NaV1.5 at potentials more hyperpolarised than -90 mV in cells that were held at -120 
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mV between sweeps (Fig. 5A – D). The best fit parameters are summarised in 
Supplementary table 3. For both variants at a holding potential of -120 mV, we 
observed a small shift in V½ of inactivation at low concentrations of either LA, with no 
other significant changes to the fitting parameters (Supp. table 3). Most notably, 
there was no depression of the maximum available current, by contrast to the 
inhibition observed at -80 mV (Fig. 3).  
The efficacy of the LAs to depress the maximum amplitude was restored (paired t-
test versus control; Supp. table 3) at hyperpolarized potentials by a higher 
concentration of either lidocaine (300 µM) or levobupivacaine (100 µM). There were 
no significant differences (two-way ANOVA) in the extent of this inhibition by either 
LA or splice variant (Fig. 5E). The ∆ V½ was generally similar to that of lower 
concentrations of LAs, except in the case of lidocaine (300 µM) on aNaV1.5, which 
caused a greater ∆ V½ than in the presence of 10 µM lidocaine (p = 0.009; t-test; 
data not shown). There was a significant influence of splice variant on ∆ V½ (two-way 
ANOVA, F1,13 = 12; p = 0.004; Fig. 5F). Paired comparisons using a Bonferroni 
correction revealed significant differences between aNaV1.5 and nNaV1.5 in the 
presence of either lidocaine (p = 0.02) or levobupivacaine (p = 0.048; Fig. 5F). 
Lidocaine significantly changed the slope of the Boltzmann fit, while levobupivacaine 
did not (paired t-test versus control; Supp. table 3).       
We extended our investigation to evaluate tonic block of aNaV1.5 at a holding 
potential of -120 mV. We compared the extent of tonic block in the presence of low 
concentrations of either LA (data from Fig. 4) with that observed in the presence of 
high concentrations of lidocaine (300 µM; Fig. 5G) and levobupivacaine (100 µM; 
Fig. 5H). Using a t-test, we found a significant increase in tonic inhibition in the 
presence of the higher concentration of either lidocaine (p < 0.0001; Fig. 5G) or 
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levobupivacaine (p < 0.0001; Fig. 5H). Taken together, our data indicate that the 
inactivated state is not required for inhibition of NaV1.5 currents by high 
concentrations of LAs, but is necessary for inhibition at lower concentrations. 
Low concentrations of lidocaine and levobupivacaine cause differential 
slowing of NaV1.5 recovery from inactivation 
Finally we investigated the rate of recovery from inactivation in the presence and 
absence of lidocaine (10 µM) or levobupivacaine (1 µM). After inhibition had 
plateaued at -80 mV the holding potential was stepped to -120 mV for 2 ms – 30 s, to 
sample recovery from inactivation (Fig. 6A, inset). The recovery data for the aNaV1.5 
(Fig. 6A) and nNaV1.5 (Fig. 6B) were fitted with double exponential functions. The 
best fit parameters are summarised in Supplementary table 4, and used to calculate 
τw values (Fig. 6C & Supp. table 4). The identity of the splice variant did not influence 
τw (two-way ANOVA, F1,28 = 0.48; p = 0.50). However, the identity of the LA did 
influence τw (F2,28 = 11.8; p < 0.0001). In the absence of LA, the mean τw values for 
recovery from inactivation did not differ. However, the τw of recovery in the presence 
of levobupivacaine was significantly slower than controls for both splice variants (p = 
0.01 for aNaV1.5; p = 0.003 for nNaV1.5; post hoc Bonferroni correction; Fig. 6C; 
Supp. table 4). The τw for lidocaine did not significantly differ from controls. The 
slowed recovery from inactivation in the presence of levobupivacaine can be mainly 
attributed to an increase in the slow time constant (Supp. table 4). An increase in the 
slow time constant was not seen in the presence of lidocaine. Taken together, our 
data indicate that low concentrations of LA alter the rate of recovery from 
inactivation, with levobupivacaine having a larger impact than lidocaine.  
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Discussion 
Lidocaine and levobupivacaine cause potent inhibition of nNaV1.5 and aNaV1.5, an 
effect that was lost at holding potentials below -80 mV. Inhibition was half maximal in 
the low micromolar range, which can be safely achieved in the blood 15,16. There was 
no difference in the potency of block of either variant by the LAs, suggesting that 
upregulation of neonatal NaV1.5 on breast 
17 and colon cancer cells is unlikely to 
provide a strategy for selectively targeting their inhibition, consistent with our 
previous findings with ropivacaine 10.  
Human cardiac myocytes have a membrane potential of approximately -90 mV 18, at 
which high micromolar concentrations of lidocaine or levobupivacaine were required 
to inhibit either NaV1.5 variant. The enhanced sensitivity to LA block, in cells with 
membrane potentials more depolarized than -90 mV, coincides with the appearance 
of prevalent inactivation, in agreement with previous observations with lidocaine, 
bupivacaine (the racemic mixture of the S- and R-enantiomers) and ropivacaine 
3,10,19,20. Indeed, the large increase in native cardiac VASC affinity for lidocaine 
caused by inactivation has been well established 21,22. Importantly, the inactivated 
state of NaV1.5 predominates at the resting membrane potential of colon cancer cells 
(approximately -40 mV) 10,23. Consistent with our previous observation with 
ropivacaine 10, both LAs shifted the peak window current (representing the 
membrane potential of peak steady state current) to potentials below -40 mV (Supp. 
fig. 1). Therefore, inactivation state-dependent high potency block provides a 
potential strategy for targeting NaV1.5 on cancer cells while sparing cardiac 
myocytes, in which VASCs recover from inactivation during repolarisation even at 
high stimulation frequencies 18.  
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Our findings support previous observations of large state-dependent block by LAs 
which overshadows any VASC subtype specificity of these and related drugs 24,25. 
There were differences observed for both NaV1.5 variants with regard to their 
responses to LAs. Levobupivacaine caused a greater depolarizing shift in the V½ of 
activation of aNaV1.5 compared to nNaV1.5. In this regard it is relevant that the high 
affinity block of NaV1.5 by LAs has been termed voltage-sensor block due a 
proposed stabilization of S4 voltage sensors in domains III and IV 2. The nNaV1.5 
variant has several alternative amino acids in the S4 of domain I, including a lysine in 
place of the aspartate at the equivalent position in aNaV1.5. This substitution leads to 
a depolarizing shift in the V½ of activation 10,17. This lysine may stabilize the voltage 
sensors in a manner similar to that of LA stabilisation in aNaV1.5, thereby masking 
this effect in nNaV1.5. 
There are developmental changes in block by lidocaine on neonatal and adult rat 
cardiac myocytes. Native neonatal VASCs are more sensitive to inhibition by 
lidocaine 26. However, this developmental effect appears to be species specific 27. 
Our observations for nNaV1.5 and aNaV1.5 suggest that any developmental changes 
in lidocaine sensitivity of human myocardial VASCs is unlikely to be explained by 
alternative NaV1.5 splicing. 
Molecules that bind to the LA site are thought to inhibit function through a similar 
mechanism 1,28. Structural modelling suggests that these drugs inhibit current 
through steric interactions with the Na+ binding sites close to the LA binding site 29. 
As expected, in our study inhibition by the two LAs was similar; however, reversal of 
NaV1.5 inactivation-dependent inhibition by levobupivacaine was slower than that of 
lidocaine. In this paradigm reversal of inhibition from slow inactivation likely 
represents a combination of recovery from slow inactivation and LA unbinding 21,30,31. 
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In the absence of LAs, both variants exhibited similar rates and contributions of fast 
and slow components of recovery from inactivation. Levobupivacaine reduced the 
slow rate of recovery from inactivation. Lidocaine, by contrast, did not affect either 
the fast or slow rates, but did somewhat increase the contribution of the slow 
component. The slower rate of slow recovery from inactivation in the presence of 
levobupivacaine could be caused by slow unbinding. Levobupivacaine is more 
hydrophobic than lidocaine due to its propylpiperidine group, and likely contributes to 
its higher potency. Additionally, highly hydrophobic inhibitors may be able to enter 
and exit the binding site via lipid fenestrations within the membrane spanning 
domains of VASCs and may remain trapped within hydrophobic pockets 28,32. This 
may result in a longer lasting reduction in Na+ entry by levobupivacaine than 
lidocaine. 
Previous studies with bupivacaine on guinea-pig heart showed that bupivacaine fails 
to unbind in diastole and causes cardiotoxicity 33. It is unclear to what extent VASC 
inhibition is involved in the cardiotoxic effects of LAs, although slowed recovery from 
inactivation is likely to be a contributing factor 34. The S-enantiomer, 
levobupivacaine, appears less toxic than the R-enantiomer, according to preclinical 
data, and may therefore cause less slowing of recovery from inactivation 35. 
However, our results demonstrate that levobupivacaine causes a greater slowing of 
recovery of NaV1.5 inactivation than lidocaine and this may contribute to its 
cardiotoxicity.  
In this study, we used recombinant NaV1.5 isoforms, which avoids confounding 
influences of multiple VASCs and simplifies interpretation. However, in cardiac 
myocytes and cancer cells additional factors may influence the function of VASC 
and/or the actions of LAs.  
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The findings from this study will inform future in vitro investigations into the 
effectiveness of LAs in inhibiting colorectal cancer cell invasion, for instance, in 
Matrigel invasion assays. Furthermore, there is considerable interest in the potential 
of LAs to reduce recurrence or metastases following surgical tumour excision. In light 
of the direct inhibitory effects on metastatic cancer cell invasion it might be 
advantageous to administer LAs intravenously or directly onto tumours prior to 
excision 10. Indeed, the activity of NaV1.5 influences expression of multiple genes 
associated with the metastatic potential of colon cancer cells, and blockade by 
lidocaine, and the associated reduction in Na+ entry, reduces the expression of these 
genes 9,11. However, in vivo, LAs are mostly bound to serum proteins and this limits 
the free concentration available to inhibit NaV1.5. Nevertheless, since low 
concentrations of lidocaine and levobupivacaine selectively interact with inactivated 
NaV1.5, our study can inform the selection of an appropriate dose which maximises 
beneficial effects on cancer progression, while minimising the likelihood of cardiac 
toxicity.  
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Figure legends: 
Figure 1. Concentration-dependence of lidocaine and levobupivacaine mediated 
inhibition of NaV1.5 currents. Traces show representative examples of voltage-
activated nNaV1.5 currents evoked by a step to 0 mV from a holding potential of -80 
mV, in the presence of increasing concentrations of lidocaine (A) or levobupivacaine 
(B). Examples of aNaV1.5 are similar and therefore not shown. Concentration-
response relationship for lidocaine (C) and levobupivacaine (D) were derived from 
normalised peak amplitudes (with respect to control) in the presence of either LA for 
aNaV1.5 (closed circles) and nNaV1.5 (open circles). The fit to the data points 
represents the logistics function. Mean best fit parameters (and statistical analysis) 
are summarised in Supplementary table 1. 
Figure 2. Current-voltage relationship of NaV1.5. (A) Representative example of a 
family of control nNaV1.5 currents evoked by a series of voltage steps (from holding 
potential of -80 mV). The voltage protocol is shown as an inset. Peak amplitudes in 
the absence or presence of 10 µM lidocaine (B) or 1 µM levobupivacaine (C) were 
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normalised to cell capacitance and plotted against the step voltage as mean current 
density values. Control current density values at each step potential were compared 
to those in the presence of LA using a paired t-test (two-tailed). Asterisks indicate the 
voltages at which the presence of LA caused a statistically significant reduction in 
current density values. Data for aNaV1.5 are similar and therefore not shown. Peak 
current amplitudes evoked by step voltages between -80 mV and +20 mV were 
converted into conductance values (see Methods) and plotted for both aNaV1.5 (D & 
F) and nNaV1.5 (E & G) in the absence (closed circles) or presence (open circles) of 
LA (10 µM lidocaine, D & E; 1 µM levobupivacaine, F & G). The solid line indicates 
the Boltzmann function fitted to the points. The best fit parameters (and their 
statistical analyses) are summarised in Supplementary table 2. Mean ∆ V½ of 
activation (H) and ∆ slope (I). The data were analysed using a two-way ANOVA with 
LA and splice variant as the factors. Asterisk indicate statistically significant 
difference following the Bonferroni correction. Statistical parameters are given in the 
text. 
Figure 3. Voltage-dependence of inactivation of NaV1.5. Peak current amplitudes 
(evoked by step voltages to 0 mV) following a pre-pulse step to between -140 mV 
and -10 mV are normalised to maximum (see Methods) and plotted for both aNaV1.5 
(A & C) and nNaV1.5 (B & D) in the absence (closed circles) or presence (open 
circles) of LA (10 µM lidocaine, A & B; 1 µM levobupivacaine, C & D). The solid line 
indicates the Boltzmann function fit to the points. The best fit parameters (and their 
statistical analyses) are summarised in Supplementary table 2. (E & F) Mean ∆ V½ of 
activation (E) and extent of inhibition of maximum available current (F). The data 
were analysed using a two-way ANOVA with LA and splice variant as the factors. 
Asterisk indicate statistically significant difference following the Bonferroni correction. 
Statistical parameters are given in the text. 
Figure 4. Lidocaine and levobupivacaine inhibition of NaV1.5 is dependent on the 
inactivated state. (A) Representative examples show nNaV1.5 currents (evoked by 
step to 0 mV from indicated holding potential) under control conditions (black trace) 
and immediately following 2 min exposure to 10 µM lidocaine (grey trace) in the 
absence of any stimulation. The extent of inhibition is plotted as mean % inhibition in 
the presence of lidocaine (10 µM) or levobupivacaine (1 µM) for both aNaV1.5 (B) 
and nNaV1.5 (C). The change in the mean % inhibition was analysed using a one-
way ANOVA (details in the text). Asterisks indicate statistical significance (p < 0.05) 
from post hoc pairwise comparisons (with Tukey corrections) versus mean % 
inhibition at -80 mV. 
Figure 5. Concentration-dependence of lidocaine and levobupivacaine stabilisation 
of the inactivated state of NaV1.5 at -120 mV. (A to D) Voltage-dependence of 
inactivation relationships and their associated Boltzmann fits were constructed as 
described in Figure 4, with the exception that the holding membrane potential was -
120 mV. Data show voltage-dependence of inactivation in the absence (closed 
circles) or in the presence of low concentrations of LA (10 µM lidocaine A & B; 1 µM 
levobupivacaine C & D; open circles) and high concentrations of LA (300 µM 
lidocaine A & B; 100 µM levobupivacaine C & D; open squares) for aNaV1.5 (A & C) 
and nNaV1.5 (B & D). The best fit parameters of the Boltzmann function (and their 
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statistical analyses) are summarised in Supplementary table 3. (E & F) Mean ∆ V½ of 
activation (E) and extent of inhibition of maximum available current (G). The data 
were analysed using a two-way ANOVA with LA and splice variant as the factors. 
Asterisk indicate statistically significant difference following the Bonferroni correction. 
Statistical parameters are given in the text. Graphs show mean % inhibition of 
lidocaine (G) and levobupivacaine (H) following 2 min exposure to low (10 µM for 
lidocaine, 1 µM for levobupivacaine) and high concentrations (300 µM for lidocaine, 
100 µM for levobupivacaine) without stimulation, with the holding membrane 
potential at -120 mV. The low concentration data is reproduced here from Figure 4 B 
& C for comparison. Asterisk indicate a statistically significant (t-test) increase in 
tonic inhibition with the higher concentration of LA. 
Figure 6. Lidocaine and levobupivacaine influence recovery from inactivation of 
NaV1.5. (A) Inset, the voltage command protocol used to test recovery from 
inactivation. (A & B) Graphs of peak current amplitudes evoked by a step voltage to 
0 mV following recovery were normalised to maximal current amplitudes and plotted 
against the recovery time. Mean fractional recovery in control (closed circles), 10 µM 
lidocaine (open circles) and 1 µM levobupivacaine (open squares) are plotted for 
aNaV1.5 (A) and nNaV1.5 (B). The lines fitted to the points represent a double 
exponential function. The best fit parameters from the double exponential function 
(and their statistical analyses) are summarised in Supplementary table 4. From these 
parameters the weighted time constant (τw) was calculated. Mean τw are plotted in 
(C). We compared mean τw using a two-way ANOVA across treatment (control, 
lidocaine, levobupivacaine) and splice variant (details of statistics in the text). 
Asterisks indicate a statistically significant change in τw versus control following the 
Bonferroni correction.  
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